AI-Based Clinical Solutions

Original source (on modern site) | Article images: [1]

NetraMark Holdings Inc. unveiled its groundbreaking AI-based clinical solution, showcasing its ability to dissect the complex factors contributing to Parkinson's Disease and other neurodegenerative disorders. Presented at the International Conference on Alzheimer's and Parkinson's Diseases, the data highlighted the capability of the company's NetraAI to identify genetic drivers within specific patients with Parkinsoon's Disease subsets. This data might shed light on critical disease pathways and offer potential insights for future treatments.

The presentation revealed how NetraAI analyzed a dataset of 588 individuals, pinpointing multiple markers associated with PD pathogenesis, particularly those intertwined with the immune system and immune responses. By employing NetraAI's AttractorAI algorithms, the analysis identified genetic drivers within patients. Key findings included the identification of RNA transcripts associated with metabolism, transcription regulation, and inflammatory responses in Parkinson's Disease patients. Moreover, the analysis revealed potential links between PD and immune-mediated functions, emphasizing the role of the innate immune system's response to microbial pathogens, possibly involving interactions with the microbiome.